ERBB2 and breast carcinoma: Korkaya and colleagues demonstrated that IL-6 was induced in HER2pos breast cancer cells by the HER2 neutralizing antibody Trastuzumab in the setting of PTEN loss, with PTEN inactivation being a known mechanism of resistance to HER2-directed therapies [59,60].